Clinical trial
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
NCT00055146 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00055146 |
|---|---|
| Title | Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) |
| Official title | A Multicenter, Phase II Study of ONTAK (Denileukin Diftitox) in Patients With Previously-Treated Chronic Lymphocytic Leukemia |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | ONTAK |
| Enrollment | 41 |
| Start date | Mar 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Feb 21, 2003 |
| Last update posted | Apr 17, 2009 |
| Countries | Argentina, Australia, Brazil, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: